Details on reported postacute health outcomes
| Study | Follow-up (months)* | Main outcome | Outcomes (n, reported/total assessed) | Outcome data collection method | Symptom duration reported | Symptom frequency reported | Symptom trend reported | Symptom severity reported | Subgroup analyses related to main outcome |
| Controlled studies | |||||||||
| Bergia et al29 | 4 (infection) | Any symptoms | 20/n.r. | Structured questionnaire by phone led by physicians | Yes | – | – | – | Yes |
| Blomberg et al25 | 6 (infection) | Any symptoms | 11/11 | Personal interview led by medical staff | – | – | – | – | – |
| Matsubara et al30 | 3 (infection) | Cardiac symptoms | 3/n.r. | Routinely collected data (medical records and structured clinical assessment) | – | – | – | – | – |
| Radtke et al27 | 6 (infection) | Any symptoms | 11 /n.r. | Structured online questionnaire | Yes | – | – | – | – |
| Roessler et al26 | 3 (infection) | Health outcomes combined | 97 (grouped)/97 | Routinely collected data (administrative claims, unclear how symptoms were assessed) | – | – | – | – | Yes |
| Stephenson et al28 | 3 (infection) | Any symptoms | 25/25 | Structured online questionnaire | – | – | – | – | Yes |
| Uncontrolled studies | |||||||||
| Asadi-Pooya et al 202131 | 8 (recovery) | Any symptoms | 28/28 | Structured questionnaire by phone (unclear who led by) | – | Yes | – | Yes | Yes |
| Bottino et al32 | 2 (recovery) | Respiratory symptoms | 1/n.r. | Clinical visit (unclear who led by and how symptoms were assessed) | – | – | – | – | – |
| Capone et al44 | 6 (infection) | Fatigue | 1/n.r. | Clinical visit (unclear who led by and how symptoms were assessed) | – | – | – | – | – |
| Chowdhury et al33 | 5 (recovery) | Any symptoms | 16/n.r. | Phone call (unclear who led by and which symptoms were assessed) | Yes | – | – | – | – |
| Denina et al34 | 4 (recovery) | Any symptoms | 1 /n.r. | Phone call (unclear who led by and which symptoms were assessed) | – | – | – | – | – |
| Isoldi et al35 | 6 (infection) | Any symptoms | 1 /n.r. | Clinical visit (unclear who led by and how symptoms were assessed) | Yes | – | – | – | – |
| Kahn et al45 | 2 (infection) | Any symptoms | 9 /n.r. | Routinely collected data (registry, structured clinical assessment) | – | – | – | – | – |
| Matteudi et al36 | 11.5 (recovery) | Any symptoms | 6 /n.r. | Phone call led by a paediatric team (unclear which symptoms were assessed) | – | – | Yes | – | Yes |
| Mei et al37 | 5 (recovery) | Any symptoms | 1/48 | Case reports, medical records, self-reports (unclear who led by and how symptoms were assessed) | – | – | – | – | – |
| Osmanov et al38 | 8.5 (recovery) | Any symptoms | 44/44 | Structured questionnaire by phone led by medical students | Yes | Yes | Yes | – | Yes |
| Patnaik et al39 | 3.5 (recovery) | Any symptoms | 1 /n.r. | Clinical visit (unclear who led by and how symptoms were assessed) | – | – | – | – | – |
| Penner et al40 | 6 (infection) | Gastrointestinal symptoms | 9/9 | Routinely collected data (medical records, structured clinical assessment) | Yes | – | Yes | – | – |
| Rusetsky et al41 | 2 (recovery) | Olfactory disorder | 1/1 | Structured questionnaire by phone led by the investigators | Yes | – | – | Yes | Yes |
| Say et al42 | 4.5 (infection) | Any symptoms | 24/24 | Clinical visit using a structured clinical assessment (unclear who led by) | Yes | – | – | – | – |
| Sterky et al43 | 7 (infection) | Any symptoms | 18/18 | Structured questionnaire by phone (unclear who conducted) | – | – | – | Yes | Yes |
*Follow-up started at detection of infection, onset of symptoms, COVID-19 diagnosis and/or hospital admission (described as infection) or at recovery from the acute illness and/or hospital discharge (described as recovery).
n.r., not reported.